Hairy Cell Leukemia and Related Disorders—Current Progress in Biology and Treatment
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 November 2024 | Viewed by 53
Special Issue Editors
Interests: cutaneous lymphomas; leukemia cutis; autoimmune; precision medicine
2. Department of General Hematology, Copernicus Memorial Hospital, 93-510 Lodz, Poland
Interests: leukemia; lymphoma; multiple myeloma; autoimmune cytopenias; targeted drugs
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Classic hairy cell leukemia (HCL) is a rare, indolent B-cell leukemia with an annual incidence of about 0.3 cases per 100,000. Its typical clinical presentation involves pancytopenia, splenomegaly, constitutional symptoms and increased susceptibility to infection. HCL-variant (HCLv) is a clinical–pathologic entity with intermediate features between classical HCL and B-cell prolymphocytic leukemia. HCL-like diseases include splenic B-cell lymphoma/leukemia, unclassifiable diseases, HCLv and splenic diffuse red pulp lymphoma (SDRPL). Biologically, HCLv is more closely related to splenic lymphomas, and together with prolymphocytic B-cell leukemia, has been reclassified by the fifth edition of the WHO Classification of Haematolymphoid Tumours (2022) as splenic B-cell lymphoma/leukemia with prominent nucleoli. Purine nucleoside analogs (PNAs), cladribine (2-CldA) and pentostatin (DCF) remain the drugs of choice in the treatment of classic HCL. New targeted drugs, including BRAF inhibitors, BTK inhibitors and venetoclax, have recently been investigated for HCL treatment. BRAF inhibitors vemurafenib and dabrafenib exhibit remarkable activity in patients with classic HCL and are used in relapsed and refractory patients. The therapeutic approach to HCLv is still debated and the results of treatment with PNA are poor. Overall, despite the evolving treatment options for both classic HCL and related disorders, they remain incurable diseases, and there is a substantial need for a better understanding of their biology and finding novel therapies.
For this Special Issue of Cancers, we welcome original research and review articles that provide an overview of the most recent advances and future challenges for the diagnosis and treatment of classic HCL and related disorders, including HCL-variant, SDRPL and other diseases.
Prof. Dr. Ewa Robak
Prof. Dr. Tadeusz Robak
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hairy cell leukemia
- cutaneous lymphomas
- leukemia cutis
- autoimmune
- precision medicine
